Central Antinociceptive Activity of Peripherally Applied Botulinum Toxin Type A in Lab Rat Model of Trigeminal Neuralgia

Overview

Journal Springerplus

Date 2016 Apr 23

PMID 27104119

Citations 21

Authors

Chuanjie Wu

Nanchang Xie

Yajun Lian

Hongliang Xu

Chen Chen

Yake Zheng

Yuan Chen

Haifeng Zhang

Affiliations

Soon will be listed here.

Abstract

Background: BoNT-A is often used in the clinical treatment for movement disorders. In recent years, various clinical studies suggest that BoNT-A can effectively alleviate pain caused by trigeminal neuralgia (TN); however, its mechanism remains unclear.

Methods: In this study, we used a lab rat model for TN produced by chronic constriction injury of the infraorbital nerve (ION-CCI). Restrained rats were injected subcutaneously with BoNT-A into the whisker pad tissue (ipsilaterally to the nerve injury) 14 days after the ION-CCI. Allodynia was tested by Von Frey filaments and TRPs and cSNAP-25 were tested by western blot.

Results: Peripheral application of BoNT-A (3, 10 U/kg) significantly increased the pain threshold of ION-CCI rats. Rota-rod test showed that BoNT-A administration at doses tested did not significantly affect rat motor coordination. By probing for a specific marker for BoNT-A, cleaved synaptosomal-associated protein 25 (cSNAP-25), we found that peripheral application of BoNT-A (10 U/kg) affected brainstem Vc, which could be blocked by the axonal transport blocker colchicine. In addition, western blot analysis showed that in the Vc region of ION-CCI rats, the expression levels of TRPA1, TRPV1, TRPV2 and TRPM8 increased, whereas peripheral application of BoNT-A significantly lowered the high expression of TRPA1, TRPV1 and TRPV2, but not TRPM8 at 7 days after BoNT-A injection.

Conclusions: The finding of this study suggest that peripherally applied BoNT-A can produce antinociceptive effects in ION-CCI model. The underlying mechanisms may be BoNT-A acts on the Vc via axonal transport, inhibits the high expression of TRPA1, TRPV1 and TRPV2, and reduces central sensitization.

Citing Articles

Botulinum Toxin Type A in Trigeminal Neuralgia Treatment: A Case Series and Literature Review.

Santos R, Machado M, Ferro M, Camoes-Barbosa A Cureus. 2024; 16(11):e73389.

PMID: 39659334 PMC: 11630620. DOI: 10.7759/cureus.73389.

Enhancing orofacial pain relief: α-phellandrene complexed with hydroxypropyl-β-cyclodextrin mitigates orofacial nociception in rodents.

Machado B, Passos F, Antoniolli A, Menezes Pereira E, Santos T, Monteiro B Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39495266 DOI: 10.1007/s00210-024-03561-2.

The odyssey of the TR(i)P journey to the cellular membrane.

Rivera B, Orellana-Serradell O, Servili E, Santos R, Brauchi S, Cerda O Front Cell Dev Biol. 2024; 12:1414935.

PMID: 39108834 PMC: 11300232. DOI: 10.3389/fcell.2024.1414935.

Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain.

Bagues A, Hu J, Alshanqiti I, Chung M Pharmacol Ther. 2024; 259:108668.

PMID: 38782121 PMC: 11182613. DOI: 10.1016/j.pharmthera.2024.108668.

OnabotulinumtoxinA effects on trigeminal nociceptors.

Moore A, Nelson M, Wickware C, Choi S, Moon G, Xiong E Cephalalgia. 2023; 43(2):3331024221141683.

PMID: 36751871 PMC: 10652784. DOI: 10.1177/03331024221141683.

References

Vos B, Strassman A, Maciewicz R . Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve. J Neurosci. 1994; 14(5 Pt 1):2708-23. PMC: 6577477. View

Xia J, He C, Zhang H, Lian Y, Chen Y, Wu C . Botulinum toxin A in the treatment of trigeminal neuralgia. Int J Neurosci. 2015; 126(4):348-53. DOI: 10.3109/00207454.2015.1019624. View

Hall G, Carroll D, Parry D, McQuay H . Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006; 122(1-2):156-62. DOI: 10.1016/j.pain.2006.01.030. View

Taylor J, Brauer S, ESPIR M . Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J. 1981; 57(663):16-8. PMC: 2424760. DOI: 10.1136/pgmj.57.663.16. View

Zakrzewska J, Linskey M . Trigeminal neuralgia. BMJ. 2014; 348:g474. DOI: 10.1136/bmj.g474. View

Xiao L, Cheng J, Zhuang Y, Qu W, Muir J, Liang H . Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. Pain Med. 2013; 14(2):276-86. DOI: 10.1111/pme.12017. View

Oh H, Chung M . Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins (Basel). 2015; 7(8):3127-54. PMC: 4549742. DOI: 10.3390/toxins7083127. View

Filipovic B, Matak I, Bach-Rojecky L, Lackovic Z . Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One. 2012; 7(1):e29803. PMC: 3251614. DOI: 10.1371/journal.pone.0029803. View

Cui M, Khanijou S, Rubino J, Aoki K . Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004; 107(1-2):125-33. DOI: 10.1016/j.pain.2003.10.008. View

10.

Neubert J, Mannes A, Keller J, Wexel M, Iadarola M, Caudle R . Peripheral targeting of the trigeminal ganglion via the infraorbital foramen as a therapeutic strategy. Brain Res Brain Res Protoc. 2005; 15(3):119-26. DOI: 10.1016/j.brainresprot.2005.05.003. View

11.

Ferrandiz-Huertas C, Mathivanan S, Wolf C, Devesa I, Ferrer-Montiel A . Trafficking of ThermoTRP Channels. Membranes (Basel). 2014; 4(3):525-64. PMC: 4194048. DOI: 10.3390/membranes4030525. View

12.

Bohluli B, Motamedi M, Bagheri S, Bayat M, Lassemi E, Navi F . Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 111(1):47-50. DOI: 10.1016/j.tripleo.2010.04.043. View

13.

Luvisetto S, Gazerani P, Cianchetti C, Pavone F . Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders. Toxins (Basel). 2015; 7(9):3818-44. PMC: 4591645. DOI: 10.3390/toxins7093818. View

14.

Dieleman J, Kerklaan J, Huygen F, Bouma P, Sturkenboom M . Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008; 137(3):681-688. DOI: 10.1016/j.pain.2008.03.002. View

15.

Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N . Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014; 15:65. PMC: 4194456. DOI: 10.1186/1129-2377-15-65. View

16.

Matak I, Riederer P, Lackovic Z . Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int. 2012; 61(2):236-9. DOI: 10.1016/j.neuint.2012.05.001. View

17.

Ngeow W, Nair R . Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109(3):e47-50. DOI: 10.1016/j.tripleo.2009.03.021. View

18.

Wu C, Lian Y, Zheng Y, Zhang H, Chen Y, Xie N . Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012; 32(6):443-50. DOI: 10.1177/0333102412441721. View

19.

Setler P . Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2003; 18(6 Suppl):S119-24. DOI: 10.1097/00002508-200211001-00002. View

20.

Brin M, Fahn S, Moskowitz C, Friedman A, Shale H, Greene P . Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987; 2(4):237-54. DOI: 10.1002/mds.870020402. View